small cell lung cancer
Conditions
Interventions
EP Group:Etoposide (VP-16), 100/m2, intravenous drip, D1 ~ D3
cisplatin (DDP), 25 mg/m2, intravenous drip, D1 ~ D3 days. 21 d for 1 cycles, 4 cycles.
Sponsors
Huangshi Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. In line with the Chinese Association for cancer, lung cancer, Specialized Committee issued the diagnostic criteria "China lung cancer clinical guidelines (2010 Edition)". By the histopathological or cytology, diagnosis is clear for the patients with a wide range of SCLC. And the chest abdominal enhanced CT, the whole body bone scan, MRI scan, are confirmed as the wide range of SCLC,according to the staging method developed by the United States veterans of lung cancer research group (VALG); 2. Man and woman aged 18-72 years old; 3. The general situation is good, the KPS score is more than 70 points, and the survival time is 3 months or more; 4. ECOG score of 0 to 1 points; 5. Cases can be first diagnosed patients, also be the patients of recurrence and metastasis after surgery or radiotherapy after not by the treatment; If received adjuvant chemotherapy, from the end of adjuvant chemotherapy at least interval of more than half a year; at least a measurement of tumor lesions. Spiral CT. The maximum diameter must be larger than or equal to 10mm, ordinary or physical examination. The maximum diameter must be equal to or greater than 10mm; 6. Patients with asymptomatic brain metastases, or patients with brain metastases after treatment for more than a week; 7. Blood, heart, lung and liver showed no obvious abnormal. 8. To support the understanding of this experiment, and willing to sign the consent form of chemotherapy and informed consent, voluntary testing, good compliance.
Exclusion criteria
Exclusion criteria: (1) Patients who did not meet the inclusion criteria; (2) Patients with severe heart disease, brain blood vessels, liver and kidney, and blood coagulation system; (3) Women during pregnancy or lactation; (4) Participating in other drug trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| short-term therapeutic effectiveness;KPS score;progression-free survival (PFS);Overall survival (OS);toxicity; | — |
Countries
China
Contacts
Public ContactJiang Lan
Huangshi Central Hospital
Outcome results
None listed